UBS (Lux) Equity Fund - Biotech (USD) QL-accRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | -3.6 | 4.5 | -3.1 | -2.0 | |
+/-Cat | - | 5.4 | 12.3 | -1.8 | -3.5 | |
+/-B’mrk | - | -3.9 | 2.0 | -10.4 | -7.8 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 21/11/2024 | USD 97.22 | |
Day Change | 0.89% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU2208649280 | |
Fund Size (Mil) 21/11/2024 | USD 416.10 | |
Share Class Size (Mil) 21/11/2024 | USD 23.09 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 18/11/2024 | 0.90% |
Investment Objective: UBS (Lux) Equity Fund - Biotech (USD) QL-acc |
The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Matthew Konosky 01/10/2017 | ||
Scott Wilkin 12/07/2024 | ||
Click here to see others | ||
Inception Date 15/09/2020 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI US IMI/BIOTECHNOLOGY 10/40 NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for UBS (Lux) Equity Fund - Biotech (USD) QL-acc | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 10.09 |
Alnylam Pharmaceuticals Inc | Healthcare | 7.33 |
Neurocrine Biosciences Inc | Healthcare | 5.12 |
Moderna Inc | Healthcare | 4.90 |
Amgen Inc | Healthcare | 4.85 |
Increase Decrease New since last portfolio | ||
UBS (Lux) Equity Fund - Biotech (USD) QL-acc |